Journal Article

1299O_PRPrimary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)

S. Novello, J. Mazieres, I-J. Oh, J. de Castro, M.R. Migliorino, A. Helland, R. Dziadziuszko, F. Griesinger, A. Kotb, A. Zeiter, A. Cardona, B. Balas, H. Johannsdottir, A. Das-Gupta and J. Wolf

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 28, issue suppl_5 Published in print September 2017 | ISSN: 0923-7534
Published online September 2017 | e-ISSN: 1569-8041 | DOI: http://dx.doi.org/10.1093/annonc/mdx440.058
1299O_PRPrimary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)

Show Summary Details

Journal Article.  539 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.